This site uses cookies to store information on your device to help us improve the experience of our visitors.

A cookie is usually a small piece of data sent from a website and stored in a user's web browser while a user is browsing a website. When the user browses the same website in the future, the data stored in the cookie can be retrieved by the website to notify the website of the user's previous activity.

To find out more about the cookies this site uses, please see the links to the left.

You can change your mind at any point and update your cookies preferences by clicking on the 'cookies' tab at the top of the page. Note: the selection below applies to this website only.

Compliance Cookie

The compliance cookie remembers the choice that is made here. No personal information is collected about you or about your computer.

Analytics Cookies

The analytics cookies measure the 'hits' on our site. They help us improve user experience by letting us know what information is the most requested, and the routes which the users take through the site. No personal information is collected about you or about your computer.

Functional/Session Cookies

Functional cookies are used for activities such as
logging in to a site and completing online forms.
They do not contain any personal information and are automatically
deleted when you close your browser.

Trimbow inhaler is a combination inhaler containing beclometasone, formoterol and glycopyrronium which has been approved as an option for COPD for patient's who require triple therapy with a LABA/LAMA/ICS.

Zerbaxa (ceftolozane/tazobactam) has been approved for in-hospital use following consultant microbiologist advice only.

October 2018

Triple inhaler therapy (LABA/LAMA/ICS) is indicated in COPD patients who are in Gold guidelines D. i.e., patients who are having more than two exacerbations a year, more symptomatic despite on dual bronchodilators with raised eosinophil counts or patients with Asthma COPD overlap syndrome.

November 2018

Trelegy inhaler is a combination inhaler containing fluticasone furoate, umeclidinium and vilanterol which is an Ellipta inhaler that has been approved as an option for COPD for patient's who require triple therapy with a LABA/LAMA/ICS.

December 2018

Symbicort 200/6 pMDI has been approved as an option for the treatment of COPD for patients who require a LABA/ICS inhaler.

Natamycin 5% eye drops (unlicensed) have been approved as hospital only treatment for fungal infection of the eye following approval from opthalmology and microbiology.

February 2019

Semaglutide has been approved as an option for the treatment of adults with inadequately controlled type 2 diabetes as an adjunct to diet and exercise. Caution: Abrupt improvement in glycaemic control has been associated with temporary worsening of retinopathy, especially when semaglutide is added to insulin therapy. Avoid adding in semaglutide to patients with active proliferative or pre-proliferative diabetic retinopathy, and/or active maculopathy or macular oedema.

Kyleena 19.5mg IUD has been approved as an option for contraception.

Jaydess 13.5mg IUD has been granted retrospective approval as an option for contraception.

Strontium ranelate has been re-instated on formulary for the treatment of severe osteoporosis in postmenopausal women and adult men at high risk of fracture who cannot use other osteoporosis treatments. The decision to prescribe should be based on an assessment of the individual patient's overall risks. Strontium is contraindicated if there is a history of heart disease, peripheral vascular disease, cerebrovascular disease, uncontrolled hypertension, current or previous VTE, temporary or permanent immobilisation or hypersensitivity to the active substance or any excipients. Treatment should be re-evaluated every 6-12 months and strontium discontinued if any of the above conditions develop. For more detailed information see the SpC and risk minimization informatiomn at https://www.medicines.org.uk/emc/rmm/1336/Document. A strontium ranelate patient alert card should be given to each patient.

Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes [TA572] March 2019.

On this website you will now see four icons for these resources rather than two. Please use BNF Legacy or BNF for Children Legacy as these will take you to the original format of the online publications which do not have any errors or omissions.